NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Lantheus Holdings Inc is a mid cap company (market value between $2 billion and $10 billion) in the Drug Manufacturers - Specialty & Generic industry.
Lantheus Holdings develops radiopharmaceutical products for detecting, treating, and monitoring diseases including cancer and Alzheimer's. The company operates through oncology therapeutics, diagnostic imaging, and strategic partnerships. Its products are used by various medical specialists and sold to hospitals and imaging centers throughout the United States, Europe, Canada, Australia, Asia-Pacific, and the Americas.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Lantheus Holdings Inc stock.
Slightly undervalued: intrinsic value $119.30 per share, market price $99.92, margin of safety 16.2% (as of 2026-10-19).
Discounting its cash flows at 9.6% (average of 3 methods) values the shares at $119.30; the price of $99.92 is 16% below that value, and 76% of that value comes from beyond year five.
Leak Score: 71/100 on 12 of 12 signals (Clear Leak).
17 more funds hold it; the full list is part of the paid plan.
All 84 Drug Manufacturers - Specialty & Generic stocks
8 more in this industry show a wider margin of safety.
LNTH is slightly undervalued (as of the 2026-10-19 close). Discounting its cash flows at 9.6% (average of 3 methods) values the shares at $119.30; the price of $99.92 is 16% below that value, and 76% of that value comes from beyond year five.
$119.30 per share (as of the 2026-10-19 close), against a market price of $99.92. That is a margin of safety of 16.2%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
71 out of 100, which we rate "Clear Leak", on 12 of 12 value investing signals.